[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hyundai Bioscience Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639752","phase-2-a-study-of-cp-cov03-compared-with-placebo-in-participants-with-dengue-part-1-and-dengue-like-illness-part-2-100639752",false,"NCT07576868","A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) \u002F Dengue and Dengue-like Illness Patients (Part 2)","Inclusion Criteria:\n\n* Patients who are 18 years or over of age at time of screening.\n* Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.\n* Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)\n\nExclusion Criteria:\n\n* Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)\n* Patients who have previously received dengue vaccine\n* Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease","ALL","18 Years",{"count":19,"type":20},210,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This is a randomized, double-blind, placebo-controlled Phase 2\u002F3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.",[27],"Dengue",[29,30,31],"dengue","dengue treatment","dengue antiviral","RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-08","ACTUAL",{"date":38,"type":36},"2026-04-09",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Hyundai Bioscience Co., Ltd.","INDUSTRY",2,""]